MRCP UK EXAMINATIONS

Detailed explanation-1: -In recent years, four direct oral anticoagulants (DOACs), dabigatran, rivaroxaban, apixaban and edoxaban, have been compared with warfarin for stroke prevention in AF, in large, phase 3, randomised, controlled trials (RCTs).

Detailed explanation-2: -Direct oral anticoagulants (DOACs)-dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the prevention of thrombosis in several cardiovascular contexts.

Detailed explanation-3: -For many decades, the vitamin K antagonists (VKAs) have been the only oral anticoagulant drugs available for clinical use for the primary and secondary prevention of venous and arterial thromboembolic events.

Detailed explanation-4: -Warfarin/coumarin (Coumadin®) Nicoumalone/acenocoumarol (Sintrom®) Phenprocoumon (Marcumar®; Falithrom®) Fluindione (Previscan®)